Low-Intermediate-Glycemic Index Caribbean Foods Versus High Glycemic Index Foods in Type 2 Diabetes
This study has been completed.
Sponsor:
University Hospital of the West Indies
Information provided by:
University Hospital of the West Indies
ClinicalTrials.gov Identifier:
NCT00818935
First received: January 6, 2009
Last updated: NA
Last verified: January 2009
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether low and intermediate GI Caribbean foods are effective in the management of type 2 diabetes.
| Condition | Intervention |
|---|---|
|
Type 2 Diabetes Inflammation Cardiovascular Disease |
Dietary Supplement: Low-Intermediate-Glycemic Index diets Dietary Supplement: High GI diet |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Investigator) Primary Purpose: Treatment |
| Official Title: | Glycemic Indices of Caribbean Foods and Application in Dietary Lifestyle Intervention for Management of Type 2 Diabetes Mellitus |
Resource links provided by NLM:
Further study details as provided by University Hospital of the West Indies:
Primary Outcome Measures:
- Glycated Haemoglobin [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- body weight, homocysteine, C-reactive protein, plasma lipids and lipoproteins, fasting body glucose, insulin, insulin resistance, serum urea, creatinine, C-peptide [ Time Frame: 6 months ] [ Designated as safety issue: No ]
| Enrollment: | 65 |
| Study Start Date: | June 2004 |
| Study Completion Date: | April 2005 |
| Primary Completion Date: | April 2005 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Low-Intermediate-Glycemic Index diets | Dietary Supplement: Low-Intermediate-Glycemic Index diets |
| Active Comparator: High GI diet | Dietary Supplement: High GI diet |
Show Detailed Description
Eligibility| Ages Eligible for Study: | 25 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- between the age group of 25-65 years who have been previously clinically diagnosed with type 2 diabetes mellitus.
- Subjects were required to have low activity jobs, for example, clerical jobs
Exclusion Criteria:
- Individuals with Impaired glucose tolerance (IGT)
- Diabetics who were treated with insulin
- Subjects who were on hypertensive medications
- Individuals who are polycythemic or anemic
- Type 2 diabetics who participate in vigorous exercise Persons with chronic disease other than diabetes making a 3-year survival improbable as well as other medical characteristics that are likely to interfere with their participation in the study, for example, subjects with unbalanced clinical conditions, such as thyroid and liver disease, which could interfere with glucose metabolism; alcoholism or inability to effectively participate in a dietary programme
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00818935
Locations
| Jamaica | |
| University of the West Indies | |
| Kingston, Jamaica | |
Sponsors and Collaborators
University Hospital of the West Indies
Investigators
| Principal Investigator: | Prof Helen N Asemota, PhD | Univeristy of the West Indies |
More Information
No publications provided
| Responsible Party: | Dr. Andrew Wheatley (Principal Investigator), University of the West Indies |
| ClinicalTrials.gov Identifier: | NCT00818935 History of Changes |
| Other Study ID Numbers: | UWI-0012 |
| Study First Received: | January 6, 2009 |
| Last Updated: | January 6, 2009 |
| Health Authority: | Jamaica: Ministry of Health |
Additional relevant MeSH terms:
|
Cardiovascular Diseases Diabetes Mellitus Diabetes Mellitus, Type 2 Inflammation |
Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Pathologic Processes |
ClinicalTrials.gov processed this record on May 16, 2013